May 13, 2020 / 8:53 PM / 15 days ago

BRIEF-Immunic Receives First Regulatory Approval From German Health Authority BfArM To Initiate Phase 2 Clinical Trial Of IMU-838 In COVID-19 Patients

May 13 (Reuters) - Immunic Inc:

* IMMUNIC, INC. RECEIVES FIRST REGULATORY APPROVAL FROM GERMAN HEALTH AUTHORITY BFARM TO INITIATE A PHASE 2 CLINICAL TRIAL OF ITS SELECTIVE ORAL DHODH INHIBITOR, IMU-838, IN COVID-19 PATIENTS

* IMMUNIC INC - DOSING OF FIRST PATIENT IS EXPECTED TO OCCUR LATER THIS MONTH FOR ITS SELECTIVE ORAL DHODH INHIBITOR, IMU-838 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below